Last reviewed · How we verify

Melatonin injection

Imperial College London · FDA-approved active Small molecule

Melatonin binds to melatonin receptors (MT1 and MT2) to regulate circadian rhythm and promote sleep-wake cycle normalization.

Melatonin binds to melatonin receptors (MT1 and MT2) to regulate circadian rhythm and promote sleep-wake cycle normalization. Used for Circadian rhythm sleep disorders, Insomnia, Sleep disturbances in hospitalized or critically ill patients.

At a glance

Generic nameMelatonin injection
Also known asCAS-73314
SponsorImperial College London
Drug classMelatonin receptor agonist
TargetMT1 and MT2 melatonin receptors
ModalitySmall molecule
Therapeutic areaNeurology / Sleep Medicine
PhaseFDA-approved

Mechanism of action

Melatonin is an endogenous hormone that acts as a chronobiotic agent, synchronizing the body's internal clock with external light-dark cycles. By activating melatonin receptors in the suprachiasmatic nucleus and other tissues, it facilitates sleep onset and maintains circadian homeostasis. The injectable formulation allows for direct systemic delivery, potentially providing more consistent pharmacokinetics than oral administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: